首页> 外文期刊>Recent patents on endocrine, metabolic & immune drug discovery >Targeting Chemokine (C-X-C motif) Receptor 3 in Thyroid Autoimmunity
【24h】

Targeting Chemokine (C-X-C motif) Receptor 3 in Thyroid Autoimmunity

机译:Targeting Chemokine (C-X-C motif) Receptor 3 in Thyroid Autoimmunity

获取原文
获取原文并翻译 | 示例
           

摘要

The C-X-C chemokine receptor (CXCR)3 and its chemokines (CXCL9, CXCL10, CXCL11) are involved in the pathogenesis of autoimmune thyroiditis (AT), Graves' disease (GD) and Graves' Ophthalmopathy (GO). Under the influence of interferon(IFN)y, the IFNy-induced protein 10 (IP-10/CXCL10) is secreted by thyrocytes, orbital fibroblasts and preadipocytes. In tissue, Thl lymphocytes are recruited; hence IFNy is enhanced, which stimulates CXCL10 secretion reiterating the autoimmune process. The presence of elevated levels of CXCL10 in peripheral liquids is considered a marker of Thl orientated immune response. High levels of circulating CXCL10 (sCXCLlO) have been shown in patients with AT, overall with hypothyroidism. In GD and GO patients high sCXCL10 have been shown particularly in the active disease. A modulatory role of peroxisome proliferator-activated receptor (PPAR)gamma or - alpha agonists on CXCR3 chemokines in AT, GD and GO and the immuno-modulatory effect of methimazole on CXCR3 chemokines in GD have been shown. Further studies are ongoing to explore the use of new molecules that act as antagonists of CXCR3, or block CXCL10, in autoimmune disorders, and many interesting patents have been recently applied.

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号